The Injection Business: How Safe Is the Swine Flu Vaccine?
Swine flu symptoms may generally be mild but in a bid to prevent a pandemic health officials and pharmaceutical companies are planning to administer a new, little-tested vaccine to millions of Germans. Meanwhile, officials in the United States are taking a more cautious approach to fighting the virus.
On first impression, anyone walking into the medical practice of Helmut Beermann these days would likely think the doctor must be a hypochondriac. A warning sign prominently displayed on the door to his practice in the southern section of Hannover in northern Germany reads: "People who believe that they could have the swine flu are barred from entering this practice." Instead, the sign instructs potential carriers of the virus to ring the doorbell four times and "wait outside for an appropriate period of time."
A GSK employee in Dresden working on the production of a vaccine for the swine flu.
"I went to his house, where I took his temperature outside and determined he had a fever," says the 55-year-old doctor.
Beermann is less concerned about his own health than about his business. "The public health department has closed the practices of five doctors I know." The agency apparently justified its action with the argument that the physicians had treated swine flu patients without wearing protective clothing.
In theory, this rule also applies to the ordinary winter flu, but health officials are uninterested in that aspect of the regulation.
The officials have been incited by the sort of media hysteria typical of the summer news slowdown. Day after day, German mass circulation newspaper Bild, for example, recounts how many vacationers have contracted the swine flu on the Mediterranean vacation island of Mallorca, most likely during inebriated viral exchanges over communal buckets of sangria. One typical alarmist headline reads: "Swine Flu: Virus Out of Control!"
The headlines have been having an impact. On the eastern edge of the Lüneburg Heath region in north-central Germany, Heinz Jarmatz, a family physician, receives about 20 inquiries a day from nervous patients wanting to know whether a vaccine is available against the flu strain yet. Jarmatz would also like to put up a sign, expect that his, as he says, would read: "The Vaccine is Not Available Yet." He predicts that once the serum becomes available, "there will be a real stampede to get it."
Does It Pose a Health Risk?
But the question is: Is it even advisable to get the supposedly protective vaccination as quickly as possible? Is the swine flu vaccine truly safe? Or does it pose a health risk?
To avoid being accused of doing nothing, government health officials are preparing a vaccination campaign unprecedented in scope. Last Friday, the health ministers of Germany's states ordered 50 million doses of the vaccine from pharmaceutical giant GlaxoSmithKline (GSK).
But their plans do not call for the standard, tried-and-tested program of vaccinations that are administered to millions of Germans each year to combat the seasonal influenza virus. Instead, new types of vaccine production processes will be used, as well as new drugs designed to boost the immune system.
In addition, the vaccine serums have passed through a uniquely accelerated approval process at the European Medicines Agency (EMEA) in London. "What we are experiencing here is a large-scale experiment being conducted on the German population," warns Wolfgang Becker-Brüser, the publisher of arznei telegram, a professional journal critical of the pharmaceutical industry.
When the plans for an accelerated mass vaccination were developed, this approach seemed justified. In 2004, a new type of killer bird flu virus known as H5N1 made headlines when it became known that the resulting illness was fatal in 60 percent of those infected. Fortunately, the virus has not (yet) proven to be highly contagious from human to human. But if the bird flu virus ever mutates, a pathogen could develop that will spread quickly and be extremely deadly. If that happens, accelerated vaccination will undoubtedly be preferable to no vaccination, all risks aside.
But the swine flu virus, or H1N1, has not proven to be a killer on anything like the same scale. Although more than 1,100 people had died from swine flu by last Friday, according to official figures, most of the victims were people with underlying conditions, in some cases severe. Pregnant women also appear to be among those at particularly high risk. In the vast majority of cases, however, the symptoms of the swine flu have been noticeably mild.
"At first I thought to myself: Will I die?" said Rupert Grint, known for his portrayal of the character Ron Weasley in the "Harry Potter" films, after contracting H1N1. "But all I had was a sore throat." According to a survey conducted by the German medical journal Ärztezeitung, "almost all physicians in private practice note that the symptoms are generally moderate."
This has led to growing calls for a more cautious approach to dealing with the swine flu. "If the course of the swine flu remains as harmless as it has been so far, a mass vaccination program would not be justified," says Matthias Gruhl, the head of the public health department in the northern city of Bremen. According to Gruhl, who is involved in preparations for a pandemic, all efforts are based "on the assumption that a second, far more serious wave of the swine flu is headed our way." However, says Gruhl, there are no signs yet that this will in fact happen.
Many in the medical community share his reservations. "Countries need to assess carefully the risks and benefits of rapid approval" of an H1N1 vaccine, writes the British medical journal The Lancet in an editorial in its current edition, "especially since the disease has so far been mild with most patients making a full recovery."
The Lancet authors emphasize, in particular, the simplified approval procedure introduced in Europe specifically for vaccines to be used in a pandemic, which permits manufacturers to apply for approval of so-called "mock-up" vaccines in advance of a pandemic. Four such vaccines were available when the pandemic began. Now the mock-up virus strain merely has to be exchanged for the current pandemic virus, which would allow for approval to be granted within a short period of time. Under the accelerated procedure, safety studies with the vaccine that would be used in actual vaccinations are no longer necessary.
Pregnant Women at Risk
According to the EMEA guidelines, tests to determine the safety of the final vaccine must only be performed during mass vaccinations. In the case of a killer virus, such a massive human experiment would be an acceptable risk, but should this also be true of an illness that often causes nothing but relatively harmless cold-like symptoms? The European drug licensing authority appears to have recognized the problem, and in late June, the EMEA quickly tightened its requirements for the documentation of vaccination-related incidents and adverse medical effects.
But this does nothing to change the fact that the clinical tests completed with the model vaccines were not particularly stringent. The EMEA guideline merely calls for safety studies in which side effects can be detected that occur in more than 1 percent of cases. In other words, nothing is known about less common vaccine-related incidents, some of which can be quite serious.
In theory, this means that of the 25 million German citizens to be vaccinated in the first stage, close to 250,000 could suffer a serious reaction to the vaccine, one that may not have been detected in the preceding safety studies.
The subjects in the clinical trials were primarily adolescents and adults, but not small children and pregnant women. H1N1 poses a particularly high risk for the latter group, which should therefore be vaccinated first. Paradoxically, however, there are virtually no data on the effects of a new adjuvant -- a component used to stretch the active ingredient -- used in the GSK vaccine on pregnant women. For this reason, says an insider, pregnant women in the United States will receive a vaccine without the adjuvant.
- Part 1: How Safe Is the Swine Flu Vaccine?
- Part 2: Americans More Cautious than Europeans
© DER SPIEGEL 32/2009
All Rights Reserved
Reproduction only allowed with the permission of SPIEGELnet GmbH